Literature DB >> 15227293

Cefamandole prophylaxis for cardiovascular surgery: a dosage comparison.

B J Zeluff1, L O Gentry.   

Abstract

For more than a decade, studies have indicated that antibiotic dosing immediately before and for a short time after surgery is effective in reducing the incidence of infectious complications of open-heart operations. At our institution we have used cefamandole, because of its broad spectrum of activity against bacteria common to the skin and respiratory system and its low toxicity. However, in response to more recent studies that threw doubt on the ability of the recommended dosing regimen (1.0 g given intravenously every six hours for three days) to maintain adequate intraoperative levels of cefamandole in heart tissue, we undertook an evaluation of a dosage of 2.0 g given intravenously every 6 hours for two days. This was a randomized study of 211 successive, evaluable, open-heart surgery patients who had no concurrent infections or cephalosporin allergy. Postoperatively, there were eight surgery-related infections (3.9%) and eight nosocomial infections in the 2.0-g dose group, compared with seven surgery-related infections (3.5%) and seven nosocomial infections in the 1.0-g dose group. These differences were not statistically significant. Tissue levels and cardiopulmonary bypass pump time were not risk factors for infection. We conclude that the 2.0-g doses over two days are no more effective than the 1.0-g doses over three days. However, when administration fees are considered, in a cost comparison, the 2.0-g dosing regimen is more economical than the 1.0-g regimen.

Entities:  

Year:  1987        PMID: 15227293      PMCID: PMC324761     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  17 in total

1.  Antibiotics and extracorporeal circulation.

Authors:  C F KITTLE; W A REED
Journal:  J Thorac Cardiovasc Surg       Date:  1961-01       Impact factor: 5.209

2.  Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

3.  Prophylaxis in surgery. Veterans Administration Ad Hoc Interdisciplinary Advisory Committee on Antimicrobial Drug Usage.

Authors: 
Journal:  JAMA       Date:  1977-03-07       Impact factor: 56.272

4.  Comparison of antimicrobial susceptibility patterns among coagulase-negative staphylococci.

Authors:  S B Price; D J Flournoy
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

5.  Penetration of cephapirin and cephalothin into the right atrial appendage and pericardial fluid of patients undergoing open-heart surgery.

Authors:  R Quintiliani; J Klimek; C H Nightingale
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

6.  Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats.

Authors:  F H Lee; R D Smyth; D R Van Harken
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

7.  Randomized comparison of cefamandole, cefazolin, and cefuroxime prophylaxis in open-heart surgery.

Authors:  T G Slama; S J Sklar; J Misinski; S W Fess
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

8.  Comparison of cephalothin and cefamandole prophylaxis during insertion of prosthetic heart valves.

Authors:  G L Archer; R E Polk; R J Duma; R Lower
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

9.  Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens.

Authors:  D A Goldmann; C C Hopkins; A W Karchmer; R M Abel; M T McEnany; C Akins; M J Buckley; R C Moellering
Journal:  J Thorac Cardiovasc Surg       Date:  1977-03       Impact factor: 5.209

10.  Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery.

Authors:  L D Mullany; M A French; C H Nightingale; H B Low; L H Ellison; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.